Irritable Bowel Syndrome (IBS)

Updated: Feb 15, 2022
  • Author: Jenifer K Lehrer, MD; Chief Editor: BS Anand, MD  more...
  • Print

Practice Essentials

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by abdominal pain and altered bowel habit in the absence of a specific and unique organic pathology, although microscopic inflammation has been documented in some patients. [1] Population-based studies estimate the prevalence of irritable bowel syndrome at 10-20% and the incidence of irritable bowel syndrome at 1-2% per year.

Signs and symptoms

Manifestations of IBS are as follows:

  • Altered bowel habit

  • Abdominal pain

  • Abdominal bloating/distention

Altered bowel habit in IBS may have the following characteristics:

  • Constipation variably results in complaints of hard stools of narrow caliber, painful or infrequent defecation, and intractability to laxatives

  • Diarrhea is usually described as small volumes of loose stool, with evacuation preceded by urgency or frequent defecation

  • Postprandial urgency is common, as is alternation between constipation and diarrhea

  • Characteristically, one feature generally predominates in a single patient, but significant variability exists among patients

Abdominal pain in IBS is protean, but may have the following characteristics:

  • Pain frequently is diffuse without radiation

  • Common sites of pain include the lower abdomen, specifically the left lower quadrant

  • Acute episodes of sharp pain are often superimposed on a more constant dull ache

  • Meals may precipitate pain

  • Defecation commonly improves pain but may not fully relieve it

  • Pain from presumed gas pockets in the splenic flexure may masquerade as anterior chest pain or left upper quadrant abdominal pain

Additional symptoms consistent with irritable bowel syndrome are as follows:

  • Clear or white mucorrhea of a noninflammatory etiology

  • Dyspepsia, heartburn

  • Nausea, vomiting

  • Sexual dysfunction (including dyspareunia and poor libido)

  • Urinary frequency and urgency have been noted

  • Worsening of symptoms in the perimenstrual period

  • Comorbid fibromyalgia

  • Stressor-related symptoms

Symptoms not consistent with irritable bowel syndrome should alert the clinician to the possibility of an organic pathology. Inconsistent symptoms include the following:

  • Onset in middle age or older

  • Acute symptoms (irritable bowel syndrome is defined by chronicity)

  • Progressive symptoms

  • Nocturnal symptoms

  • Anorexia or weight loss

  • Fever

  • Rectal bleeding

  • Painless diarrhea

  • Steatorrhea

  • Gluten intolerance

See Presentation for more detail.


The Rome IV criteria for the diagnosis of irritable bowel syndrome require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following [2] :

  • Related to defecation (may be increased or unchanged by defecation)

  • Associated with a change in stool frequency

  • Associated with a change in stool form or appearance

The Rome IV criteria (May 2016) only requires recurrent abdominal pain in defining this condition; "discomfort" is no longer a requirement owing to its nonspecificity. [2]

Supporting symptoms include the following:

  • Altered stool frequency

  • Altered stool form

  • Altered stool passage (straining and/or urgency)

  • Mucorrhea

  • Abdominal bloating or subjective distention

Four bowel patterns may be seen with irritable bowel syndrome, and these remain in the Rome IV classification. [2] These patterns include the following:

  • IBS-D (diarrhea predominant)

  • IBS-C (constipation predominant)

  • IBS-M (mixed diarrhea and constipation)

  • IBS-U (unclassified; the symptoms cannot be categorized into one of the above three subtypes)

The usefulness of these subtypes is debatable. Notably, within 1 year, 75% of patients change subtypes, and 29% switch between constipation-predominant IBS and diarrhea-predominant IBS. The Rome IV criteria differ from the Rome III criteria in basing bowel habit on stool forms solely during days with abnormal bowel movements rather than on the total number of bowel movements. [2]

A comprehensive history, physical examination, and tailored laboratory and radiographic studies can establish a diagnosis of irritable bowel syndrome in most patients. The American College of Gastroenterologists does not recommend laboratory testing or diagnostic imaging in patients younger than 50 years with typical IBS symptoms and without the following “alarm features” [3] :

  • Weight loss

  • Iron deficiency anemia

  • Family history of certain organic GI illnesses (eg, inflammatory bowel disease, celiac sprue, colorectal cancer)

Screening studies to rule out disorders other than IBS include the following:

  • Complete blood cell count with differential to screen for anemia, inflammation, and infection

  • A comprehensive metabolic panel to evaluate for metabolic disorders and to rule out dehydration/electrolyte abnormalities in patients with diarrhea

  • Stool examinations for ova and parasites, enteric pathogens, leukocytes, Clostridium difficile toxin, and possibly Giardia antigen

History-specific studies include the following:

  • Hydrogen breath testing to exclude bacterial overgrowth in patients with diarrhea and to screen for lactose and/or fructose intolerance

  • Tissue transglutaminase antibody testing and small bowel biopsy in IBS-D to diagnose celiac disease.

  • Thyroid function tests

  • Serum calcium testing to screen for hyperparathyroidism

  • Erythrocyte sedimentation rate and C-reactive protein measurement are nonspecific screening tests for inflammation

See Workup for more detail.


Management of irritable bowel syndrome consists primarily of providing psychological support and recommending dietary measures. Pharmacologic treatment is adjunctive and should be directed at symptoms.

Dietary measures may include the following:

  • Fiber supplementation may improve the symptoms of constipation and diarrhea

  • Polycarbophil compounds (eg, Citrucel, FiberCon) may produce less flatulence than psyllium compounds (eg, Metamucil)

  • Judicious water intake is recommended in patients who predominantly experience constipation

  • Caffeine avoidance may limit anxiety and symptom exacerbation

  • Legume avoidance may decrease abdominal bloating

  • Lactose, fructose, and/or FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) should be limited or avoided in patients with these contributing disorders

  • Probiotics are being studied for their use in decreasing IBS symptoms

Although the evidence is mixed regarding long-term improvement in GI symptoms with successful treatment of psychiatric comorbidities, the American College of Gastroenterology has recommended the following:

  • Psychological interventions, cognitive-behavioral therapy, dynamic psychotherapy, and hypnotherapy are more effective than placebo

  • Relaxation therapy is no more effective than usual care

Pharmacologic agents used for the management of symptoms in IBS include the following:

  • Anticholinergics/antispasmodics (eg, dicyclomine, hyoscyamine, trimebutine, peppermint oil) [4]

  • Antidiarrheals (eg, diphenoxylate, loperamide)

  • Tricyclic antidepressants (eg, imipramine, amitriptyline)

  • Prokinetic agents

  • Bulk-forming laxatives

  • Serotonin receptor antagonists (eg, alosetron, tegaserod)

  • Chloride channel activators (eg, lubiprostone)

  • Guanylate cyclase C (GC-C) agonists (eg, linaclotide, plecanatide)

  • Altering bacterial flora and gas formation (eg, rifaximin) [5]

  • Sodium-hydrogen exchange 3 (NHE3) inhibitors (eg, tenapanor) [6]

See Treatment and Medication for more detail.

Irritable Bowel Syndrome (IBS). What is IBS? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.


Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by abdominal pain and altered bowel habit in the absence of a specific and unique organic pathology. Osler coined the term mucous colitis in 1892 when he wrote of a disorder of mucorrhea and abdominal colic with a high incidence in patients with coincident psychopathology. Since then, the syndrome has been referred to by sundry terms, including spastic colon, irritable colon, and nervous colon.

In the past, irritable bowel syndrome has been considered a diagnosis of exclusion; however, it is no longer considered a diagnosis of exclusion, but it does have a broad differential diagnosis. [7] No specific motility or structural correlates have been consistently demonstrated; however, experts suggest that the use of available guidelines can minimize testing and aid in the diagnosis.



Traditional theories regarding the pathophysiology of irritable bowel syndrome (IBS) may be visualized as a three-part complex of altered gastrointestinal (GI) motility, visceral hyperalgesia, and psychopathology. [8] More recently, it is believed that components of the gut microbiota potentially influence brain morphology and function, behavior, and cognition, which expands the paradigm of the gut-brain axis. [9] A unifying mechanism is still unproven.

Altered GI motility

Altered GI motility includes distinct aberrations in the small and large bowel motility.

The myoelectric activity of the colon is composed of background slow waves with superimposed spike potentials. Colonic dysmotility in irritable bowel syndrome manifests as variations in slow-wave frequency and a blunted, late-peaking, postprandial response of spike potentials. Patients who are prone to diarrhea demonstrate these alterations to a greater degree than patients who are prone to constipation.

Small bowel dysmotility manifests in delayed meal transit in patients prone to constipation and in accelerated meal transit in patients prone to diarrhea. In addition, patients exhibit shorter intervals between migratory motor complexes (the predominant interdigestive small bowel motor patterns).

Current theories integrate these widespread motility aberrations and hypothesize a generalized smooth muscle hyperresponsiveness. They describe increased urinary symptoms, including frequency, urgency, nocturia, and hyperresponsiveness to methacholine challenge.

Visceral hyperalgesia

Visceral hyperalgesia is the second part of the traditional three-part complex that characterizes irritable bowel syndrome. [10]

Enhanced perception of normal motility and visceral pain characterizes irritable bowel syndrome. Rectosigmoid and small bowel balloon inflation produces pain at lower volumes in patients than in controls. Notably, hypersensitivity appears with rapid but not with gradual distention.

Patients who are affected describe widened dermatomal distributions of referred pain. Sensitization of the intestinal afferent nociceptive pathways that synapse in the dorsal horn of the spinal cord provides a unifying mechanism.


Psychopathology is the third aspect. Associations between psychiatric disturbances and irritable bowel syndrome pathogenesis are not clearly defined.

Patients with psychological disturbances relate more frequent and debilitating illness than control populations. Patients who seek medical care have a higher incidence of panic disorder, major depression, anxiety disorder, and hypochondriasis than control populations. A study has suggested that patients with irritable bowel syndrome may have suicidal ideation and/or suicide attempts strictly as a result of their bowel symptoms. [11] Clinical alertness to depression and hopelessness is mandatory. This is underscored by another study that revealed that patient complaints that relate to functional bowel disorders may be trivialized.

An Axis I disorder coincides with the onset of GI symptoms in as many as 77% of patients. A higher prevalence of physical and sexual abuse has been demonstrated in patients with irritable bowel syndrome. Whether psychopathology incites the development of irritable bowel syndrome or vice versa remains unclear.

Microscopic inflammation

Microscopic inflammation has been documented in some patients. [1] This concept is groundbreaking in that irritable bowel syndrome had previously been considered to have no demonstrable pathologic alterations.

Both colonic inflammation and small bowel inflammation have been discovered in a subset of patients with irritable bowel syndrome, as well as in patients with the onset of irritable bowel syndrome after an episode of infectious enteritis (postinfectious irritable bowel syndrome). Risk factors for developing postinfectious irritable bowel syndrome include longer duration of illness, the type of pathogen involved, smoking, female gender, an absence of vomiting during the infectious illness, and young age. [12]

Laparoscopic full-thickness jejunal biopsy samples revealed infiltration of lymphocytes into the myenteric plexus and intraepithelial lymphocytes in a subset of patients in one study. [13] Neuronal degeneration of the myenteric plexus was also present in some patients.

Patients with postinfectious irritable bowel syndrome may have increased numbers of colonic mucosal lymphocytes and enteroendocrine cells. Enteroendocrine cells in postinfectious irritable bowel syndrome appear to secrete high levels of serotonin, increasing colonic secretion and possibly leading to diarrhea.

Alterations in the intestinal biome

Small bowel bacterial overgrowth has been heralded as a unifying mechanism for the symptoms of bloating and distention, common to patients with irritable bowel syndrome. This has led to proposed treatments with probiotics and antibiotics.

The fecal microflora also differs among patients with irritable bowel syndrome versus controls. A sophisticated molecular analysis suggested an alteration in the patterns and the contents of gut bacteria. [14]



The causes of irritable bowel syndrome remain poorly defined, but they are being avidly researched.

Postulated etiologies of irritable bowel syndrome

Abnormal transit profiles and an enhanced perception of normal motility may exist. Up to one third of patients with irritable bowel syndrome may have altered colonic transit. Delayed colonic motility may be more common in patients with constipation-predominant irritable bowel syndrome than in healthy controls. Similarly, accelerated colonic transit may be more common in patients with diarrhea-predominant disease than in healthy controls. [15] Local histamine sensitization of the afferent neurons causing earlier depolarization may occur.

Causes related to enteric infection

Colonic muscle hyperreactivity and neural and immunologic alterations of the colon and small bowel may persist after gastroenteritis. Psychological comorbidity independently predisposes the patient to the development of postinfectious irritable bowel syndrome. Psychological illness may create a proinflammatory cytokine milieu, leading to irritable bowel syndrome through an undefined mechanism after acute infection.

Infection with Giardia lamblia has been shown to lead to an increased prevalence of irritable bowel syndrome, as well as chronic fatigue syndrome. In a historic cohort study of patients with G lamblia infection as detected by stool cysts, the prevalence of irritable bowel syndrome was 46.1% for as long as 3 years after exposure, compared with 14% in controls. [16]

Central neurohormonal mechanisms

Abnormal glutamate activation of N- methyl-D- aspartate (NMDA) receptors, activation of nitric oxide synthetase, activation of neurokinin receptors, and the induction of calcitonin gene–related peptide have been observed.

The limbic system mediation of emotion and autonomic response enhances bowel motility and reduces gastric motility to a greater degree in patients who are affected than in controls. Limbic system abnormalities, as demonstrated by positron emission tomography, have been described in patients with irritable bowel syndrome and in those with major depression.

The hypothalamic-pituitary axis may be intimately involved in the pathogenesis of IBS. Motility disturbances correspond to an increase in the hypothalamic corticotropin-releasing factor (CRF) production in response to stress. CRF antagonists eliminate these changes.

Additional etiologic factors

Intestinal permeability

Intestinal permeability appears to be increased, especially in diarrhea-predominant irritable bowel syndrome. [17]

Alterations in the intestinal biome

As discussed in Pathophysiology, Pimentel and colleagues have proposed that small bowel bacterial overgrowth provides a unifying mechanism for the common symptoms of bloating and gaseous distention in patients with irritable bowel syndrome. [18]

There is a relationship between the organisms that live in the intestine and the immune system, and this relationship is not yet fully understood. [17, 19]

Dietary intolerance

Bloating and distention may also occur from intolerance to dietary fats. Reflex-mediated small bowel gas clearance is more impaired by the ingestion of lipids in patients with irritable bowel syndrome than in patients without the disorder.

Studies of elimination and challenge diets have suggested that poorly absorbed short-chain carbohydrates, in the form of fructose and fructans, may create symptoms among adult patients with irritable bowel syndrome, as measured by a visual analogue scale. [20] Fructans have also been found to exacerbate the symptoms (abdominal pain, bloating, hydrogen production) in a subset of children with irritable bowel syndrome, but fructan sensitivity could not be identified on the basis of baseline gastrointestinal symptoms, dietary intake, psychosocial factors, or gas production. [21]

Evidence exists showing an association between functional variants in the sucrase-isomaltase (SI) gene and an increased risk of irritable bowel syndrome. In one study, investigators sequenced SI exons in seven familial cases, as well as screened for four congenital sucrase-isomaltase deficiency (CSID) mutations and a common SI coding polymorphism in a multicenter cohort comprised of 1887 patients and control subjects, and found that individuals affected by the SI mutations that code for defective or enzymatic activity in disaccharides had a predisposition to irritable bowel syndrome. [22] Similarly, another multinational genotype study of 2207 patients indicates that there is an increased prevalence of rare sucrase-isomaltase pathogenic variants in those affected by irritable bowel syndrome. [23]

Research suggests that neuronal degeneration and myenteric plexus lymphocytosis may exist in the proximal jejunum. Additionally, colonic lymphocytosis and enteroendocrine cell hyperplasia have been demonstrated in some patients.



Population-based studies estimate the prevalence of irritable bowel syndrome (IBS) at 10-20% [24] and the incidence of irritable bowel syndrome at 1-2% per year. However, when a 2016 population-based study compared the prevalence of irritable bowel syndrome with the Rome IV criteria versus the Rome III criteria in the United States, Canada, and the United Kingdom, investigators reported a nearly 50% reduction in its prevalence in these countries—potentially attributable to removing "discomfort" from the definition. [25]

Of people with irritable bowel syndrome, approximately 10-20% seek medical care. An estimated 20-50% of gastroenterology referrals relate to this symptom complex. The incidence is markedly different among countries.

American and European cultures demonstrate similar frequencies of irritable bowel syndrome across racial and ethnic lines. However, within the United States, survey questionnaires indicate a lower prevalence of irritable bowel syndrome in Hispanics in Texas and Asians in California. Populations of Asia and Africa may have a lower prevalence of irritable bowel syndrome. The role of different cultural influences and varying health care–seeking behaviors is unclear.

Adolescent and young adult women are most commonly affected. [9] In Western countries, women are 2-3 times more likely to develop irritable bowel syndrome than men, although males represent 70-80% of patients with irritable bowel syndrome in the Indian subcontinent. Women seek health care more often, but the irritable bowel syndrome–specific influence of this occurrence remains unknown. Other factors, such as a probably greater incidence of abuse in women, may confound the interpretation of this statistic.

Patients often retrospectively note the onset of abdominal pain and altered bowel habit in childhood. Approximately 50% of people with irritable bowel syndrome report symptoms beginning before age 35 years. The development of symptoms in people older than 40 years does not exclude irritable bowel syndrome but should prompt a closer search for an underlying organic etiology.



Irritable bowel syndrome is a chronic relapsing disorder characterized by recurrent symptoms of variable severity; however, life expectancy remains similar to that of the general population. Clinicians must be forthcoming with patients because knowledge of the condition may help allay undue fears as their disease waxes and wanes. Irritable bowel syndrome (IBS) does not increase mortality, or the risk of inflammatory bowel disease or cancer.

Patients with irritable bowel syndrome may carry an increased risk of ectopic pregnancy and miscarriage, but not stillbirth. The reasons for this are unknown. Whether the risk increases because of IBS itself, or because of another factor such as medications used for irritable bowel syndrome, is unknown. [26]

The principal associated physical morbidities of irritable bowel syndrome include abdominal pain and lifestyle modifications secondary to altered bowel habits. Work absenteeism resulting in lost wages is more frequent in patients with irritable bowel syndrome.

There appears to be an increased prevalence of comorbid anxiety and depression among patients with IBS, and these are associated with lower socioeconomic status and lower average per capita income. [27] Clinicians therefore should consider a biopsychosocial model of illness in these patients.


Patient Education

Patient education remains the cornerstone of successful treatment of irritable bowel syndrome. Teach the patient to identify stressors and to develop avoidance techniques. Many patients successfully manage their symptoms with attention to dietary triggers.

For patient education resources, see Digestive Disorders Center, as well as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Chronic Pain.

Clinicians may also wish to refer patients to the following short video, which provides a simplified but clear and concise overview about what irritable bowel syndrome is, and its epidemiology, risk factors, and management options, as well as a brief explanation of the difference between irritable bowel syndrome and inflammatory bowel disease.

Irritable Bowel Syndrome (IBS). What is IBS? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.